Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Research

Background:

• Combinatorial synthesis enables rapid screening of compound libraries for biological activity.
• Rhenium complexes are explored for their potential therapeutic applications.

Purpose of the Study:

• To synthesize and evaluate a library of rhenium(I) tricarbonyl complexes with diimine ligands for anticancer activity.
• To investigate the mechanism of action and in vivo properties of a lead rhenium compound.

Main Methods:

• Microwave-assisted combinatorial chemistry for library synthesis.
• Anticancer activity screening in three cancer cell lines.
• Characterization using NMR, mass spectrometry, elemental analysis, and X-ray crystallography.
• Mechanism of action studies including flow cytometry and morphological analysis.
• In vivo biodistribution and stability assessment using a technetium-99m analogue.

Main Results:

• Successfully synthesized 80 rhenium(I) tricarbonyl complexes.
• Identified three lead compounds with sub-10 μM anticancer activity.
• The lead compound Re-9D demonstrated potent activity against ovarian cancer cells, including cisplatin-resistant lines.
• Re-9D induces necrosis via rapid plasma membrane rupture, without cell cycle arrest.
• A ^99mTc analogue of Re-9D showed high metabolic stability and favorable biodistribution in mice.

Conclusions:

• Combinatorial synthesis is an effective strategy for discovering novel rhenium-based anticancer agents.
• Re-9D represents a promising lead compound with a unique mechanism of action and potential for overcoming drug resistance.
• Further development of Re-9D and related rhenium complexes warrants investigation for cancer therapy.